Skip to main content

Utilization of a Lentiviral System for the Generation of B Cells with Regulatory Properties

  • Protocol
  • First Online:
Regulatory B Cells

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1190))

Abstract

B cells are classically considered for their unique capacity to produce antibodies. Besides this, B cells can also present antigen, costimulate T cells, and secrete cytokines. Recent studies have demonstrated that activated B cells could regulate immunity by the secretion of anti-inflammatory cytokines. Because of their capacity to inhibit immune responses, B cells became of interest as a potential vehicle for the treatment of autoimmune disorders via cell-based therapy. Different approaches have been developed to empower B cells with regulatory properties. An attractive strategy involves their genetic engineering to enforce their expression of suppressive genes. This can be achieved using retroviral vectors. However, most retroviral vectors require prior activation of the B cells for transduction, and the administration of activated B cells may lead to unpredictable outcomes in recipients, including to an enhancement of immune responses. In contrast, resting B cells are poorly immunogenic and therefore safer for the suppression of undesired immune responses in adoptive cell therapy. In this chapter, we describe an approach to generate genetically modified resting B cells with lentiviral vectors using a protocol that is rapid, simple, and neither requires nor induces activation of B cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderton SM, Fillatreau S (2008) Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 4(12):657–666

    Article  CAS  PubMed  Google Scholar 

  2. Duddy M, Niino M, Adatia F et al (2007) Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092–6099

    Article  CAS  PubMed  Google Scholar 

  3. Fillatreau S, Sweenie CH, McGeachy MJ et al (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944–950

    Article  CAS  PubMed  Google Scholar 

  4. Scott DW (2010) Gene therapy for immunological tolerance: using “transgenic” B cells to treat inhibitor formation. Haemophilia 16(102):89–94

    Article  CAS  PubMed  Google Scholar 

  5. Schultze JL, Michalak S, Seamon MJ et al (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100:2757–2765

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Ito O, Harada M, Takenoyama M et al (1998) Vaccination with activated B cells pulsed with tumor-lysates can induce tumor specific CD4 + T cells in vivo. Immunobiology 199(1):133–147

    Article  CAS  PubMed  Google Scholar 

  7. Eynon EE, Parker DC (1992) Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175:131–138

    Article  CAS  PubMed  Google Scholar 

  8. Fuchs EJ, Matzinger P (1992) B cells turn off virgin but not memory T cells. Science 258:1156–1159

    Article  CAS  PubMed  Google Scholar 

  9. Calderón-Gómez E, Lampropoulou V, Shen P et al (2011) Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalitis. Eur J Immunol 41:1696–1708

    Article  PubMed Central  PubMed  Google Scholar 

  10. Naldini L, Blömer U, Gallay P et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263–267

    Article  CAS  PubMed  Google Scholar 

  11. Zennou V, Petit C, Guetard D et al (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185

    Article  CAS  PubMed  Google Scholar 

  12. Rubinson DA, Dillon CP, Kwiatkowski AV et al (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401–406

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Simon Fillatreau Ph.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Calderón-Gómez, E., Fillatreau, S. (2014). Utilization of a Lentiviral System for the Generation of B Cells with Regulatory Properties. In: Vitale, G., Mion, F. (eds) Regulatory B Cells. Methods in Molecular Biology, vol 1190. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1161-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1161-5_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1160-8

  • Online ISBN: 978-1-4939-1161-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics